tbuckley/cabot-search huggingface dataset:
Cyclosporine for Reperfusion Injury After Cardiac Arrest
Authors: Lance B. Becker, Peter B. Berger
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Bone Marrow (BM) Versus Peripheral Blood Stem Cell (PBSC) For Haploidentical Transplantation With Nonmyeloblative (NMA) Conditioning Regimen and Post Infusion Cyclophosphamide
Authors: Luca Castagna, Roberto Crocchiolo, Sabine Furst, Stefania Bramanti, Barbara Sarina, Jean El-Cheikh, Samia Harbi, Angela Granata, Elisa Mauro, Carmelo Carlo-Stella, Armando Santoro, Didier Blaise
Journal: Blood (2013)
Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Authors: Ian Flinn, Mark Brunvand, Martin JS Dyer, Peter Hillman, Jeffrey Jones, James Lymp, Mostafa Elhamy, Gregory Vosganian, Jane Huang, Thomas J. Kipps
Journal: Blood (2014)
Comparison of Points of Departure for Health Risk Assessment Based on High-Throughput Screening Data
Authors: Salomon Sand, Fred Parham, Christopher J. Portier, Raymond R. Tice, Daniel Krewski
Journal: Environmental Health Perspectives (2016)

The National Research Council's vision for toxicity testing in the 21st century anticipates that points of departure (PODs) for establishing human exposure guidelines in future risk assessments will increasingly be based on in vitro high-throughput screening (HTS) data.The aim of this study was to compare different PODs for HTS data. Specifically, benchmark doses (BMDs) were compared to the signal-to-noise crossover dose (SNCD), which has been suggested as the lowest dose applicable as a POD.Hill models were fit to > 10,000 in vitro concentration-response curves, obtained for > 1,400 chemicals tested as part of the U.S. Tox21 Phase I effort. BMDs and lower confidence limits on the BMDs (BMDLs) corresponding to extra effects (i.e., changes in response relative to the maximum response) of 5%, 10%, 20%, 30%, and 40% were estimated for > 8,000 curves, along with BMDs and BMDLs corresponding to additional effects (i.e., absolute changes in response) of 5%, 10%, 15%, 20%, and 25%. The SNCD, defined as the dose where the ratio between the additional effect and the difference between the upper and lower bounds of the two-sided 90% confidence interval on absolute effect was 1, 0.67, and 0.5, respectively, was also calculated and compared with the BMDLs.The BMDL40, BMDL25, and BMDL18, defined in terms of extra effect, corresponded to the SNCD1.0, SNCD0.67, and SNCD0.5, respectively, at the median. Similarly, the BMDL25, BMDL17, and BMDL13, defined in terms of additional effect, corresponded to the SNCD1.0, SNCD0.67, and SNCD0.5, respectively, at the median.The SNCD may serve as a reference level that guides the determination of standardized BMDs for risk assessment based on HTS concentration-response data. The SNCD may also have application as a POD for low-dose extrapolation.
Utilization of prescription-assistance program for medically uninsured cancer patients: A case study of a public hospital experience in New York state.
Authors: Limin Gao, Jivin Joseph, Marcelle Levy-Santoro, Vladimir Gotlieb, Alan S. Multz
Journal: Journal of Clinical Oncology (2013)

e17537 Background: With the advances in early detection, prevention, and treatment of some cancers, mortality rates in the United States have been consistently falling. However, with these successes have come substantial increases in the cost of cancer care. Antineoplastics are the leading therapeutic classes in hospital drug expenditures. Lack of insurance is associated with lower rates of cancer screening, later stage at diagnosis, and increased cancer mortality. Prescription assistance programs (PAPs) are offered by pharmaceutical manufacturers to provide medications at no out-of-pocket cost to medically indigent patients. To assist the Cancer Care Center at NUMC with drug costs for chemotherapies and maintain the quality care for patients, the Pharmacy department instituted a Patient Assistance Program (PAP) to obtain medication from the drug companies at no cost. NUMC is a “safety net” teaching hospital in suburban New York. It serves mostly an indigent population and is a Level 1 Trauma Center with over 77,000 emergency department visits per year. Methods: We followed all patients requiring assistance with chemotherapy who enrolled in our PAPs from January 1, 2011 to December 31, 2012. Individuals potentially eligible for PAPs were identified by Oncologists and by the pharmacy department. Medications included both oral and parenteral chemotherapy drugs and antiemetics. Results: The program served 341 patients in 2011 and 579 patients in 2012. The total number of visits in the clinic over 24 months was 9,405. The total cost savings of the medications was $908,944.11 in 2011 and $1,715,538.37 in 2012. Conclusions: PAPs provide a valuable safety net to ensure that cancer patients without insurance receive needed prescription medications. The rising cost of health care and the high proportion of indigent patients have financially burdened the hospital. A pharmacy-based program to procure free medications for uninsured cancer outpatients has helped to defray the Cancer Care Center’s expense of providing care at NUMC, increased patients’ compliance with chemo-protocols and allowed many patients to receive the treatment they otherwise would not be able to afford.
Measurement of Reactive Oxygen Species, Reactive Nitrogen Species, and Redox-Dependent Signaling in the Cardiovascular System
Authors: Kathy K. Griendling, Rhian M. Touyz, Jay L. Zweier, Sergey Dikalov, William Chilian, Yeong-Renn Chen, David G. Harrison, Aruni Bhatnagar
Journal: Circulation Research (2016)

Reactive oxygen species and reactive nitrogen species are biological molecules that play important roles in cardiovascular physiology and contribute to disease initiation, progression, and severity. Because of their ephemeral nature and rapid reactivity, these species are difficult to measure directly with high accuracy and precision. In this statement, we review current methods for measuring these species and the secondary products they generate and suggest approaches for measuring redox status, oxidative stress, and the production of individual reactive oxygen and nitrogen species. We discuss the strengths and limitations of different methods and the relative specificity and suitability of these methods for measuring the concentrations of reactive oxygen and reactive nitrogen species in cells, tissues, and biological fluids. We provide specific guidelines, through expert opinion, for choosing reliable and reproducible assays for different experimental and clinical situations. These guidelines are intended to help investigators and clinical researchers avoid experimental error and ensure high-quality measurements of these important biological species.
Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT
Authors: Gowri L. Kanthan, Michael A. Izard, Louise Emmett, Edward Hsiao, Geoffrey Paul Schembri
Journal: Clinical Nuclear Medicine (2016)

Ga prostate-specific membrane antigen (PSMA) PET/CT is a relatively new and highly sensitive imaging modality used in staging metastatic prostate cancer. We report a case of a 65-year-old man with newly diagnosed prostate carcinoma who had a PSMA PET/CT scan for staging of his disease. A PSMA-avid right pelvic mass was identified anterior to the sacrum. Surgical removal and histopathological examination of this lesion revealed the diagnosis of schwannoma. It is important to be aware that schwannoma may also show avid uptake on PSMA PET/CT scan and may potentially lead to an incorrect diagnosis of metastatic prostate carcinoma.
Neoadjuvant as Future for Drug Development in Breast Cancer—Letter
Authors: Marc Buyse, Tomasz Burzykowski, Everardo D. Saad
Journal: Clinical Cancer Research (2016)

We agree with DeMichele and colleagues ([1][1]) that “the neoadjuvant approach presents the opportunity to speed drug development while simultaneously providing real-time benefits to patients who participate in such trials.” Yet, the statistical argument they use to support their claim is flawed
Quantitative Monitoring of NPM1 Mutation A Minimal Residual Disease Identifies Patients At High Risk for Relapse within the ELN Favorable Risk Group
Authors: Max Hubmann, Marion Subklewe, Thomas Köhnke, Stephanie Schneider, Annika Dufour, Evelyn Zellmeier, Michael Fiegl, Wolfgang Hiddemann, Karsten Spiekermann
Journal: Blood (2012)
Studies in Species Adaptation. IV. Continuous and Discontinuous Exposure of a Flat Worm to Methylcholanthrene and to Phenanthrene
Authors: Dorothy Calnan, R. R. Spencer
Journal: JNCI Journal of the National Cancer Institute (1945)

Studies in Species Adaptation. IV. Continuous and Discontinuous Exposure of a Flat Worm to Methylcholanthrene and to Phenanthrene Get access Dorothy Calnan, Dorothy Calnan junior bacteriologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar R. R. Spencer R. R. Spencer Chief National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 3, December 1945, Pages 155–156, https://doi.org/10.1093/jnci/6.3.155 Published: 01 December 1945
Determination on Poliomyelitis Antibody Titers from Routine Immunizations
Authors: M Q JENKINS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors
Authors: Petra Temming, Marina Arendt, Anja Viehmann, Lewin Eisele, Claudia H.D. Le Guin, Michael M. Schündeln, Eva Biewald, Jennifer Mäusert, Regina Wieland, Norbert Bornfeld, Wolfgang Sauerwein, Angelika Eggert, Dietmar R. Lohmann, Karl-Heinz Jöckel
Journal: Journal of Clinical Oncology (2016)

Purpose Intraocular retinoblastoma is curable, but survivors with a heritable predisposition are at high risk for second malignancies. Because second malignancies are associated with high mortality, prognostic factors for second malignancy influence long-term overall survival. This study investigates the impact of all types of eye-preserving therapies on long-term survival in the complete German cohort of patients with heritable retinoblastoma. Patients and Methods Overall survival, disease staging using international scales, time period of diagnosis, and treatment type were analyzed in the 633 German children treated at the national reference center for heritable retinoblastoma. Results The 5-year overall survival of children diagnosed in Germany with heritable retinoblastoma between 1940 and 2008 was 93.2% (95% CI, 91.2% to 95.1%), but long-term mortality was increased compared with patients with nonheritable disease. Overall survival correlated with tumor staging, and 92% of patients were diagnosed with a favorable tumor stage (International Retinoblastoma Staging System stage 0 or I). Despite a 5-year overall survival of 97.4% (95% CI, 96.0% to 98.8%) in patients with stage 0 or I, only 79.5% (95% CI, 74.2% to 84.8%) of these patients survived 40 years after diagnosis. Long-term overall survival was reduced in children treated with eye-preserving radiotherapy compared with enucleation alone, and adding chemotherapy aggravated this effect. Conclusion The benefits of preserving vision must be balanced with the impact of eye-preserving treatments on long-term survival in heritable retinoblastoma, and the genetic background of the patient influences choice of eye-preserving treatment. Germline RB1 genetic analysis is important to identify heritable retinoblastoma among unilateral retinoblastoma cases. Eye-preserving radiotherapy should be carefully considered in patients with germline RB1 mutations. Life-long oncologic follow-up is crucial for all retinoblastoma survivors, and less detrimental eye-preserving therapies must be developed.
Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients
Authors: A R Koreen, J Lieberman, J Alvir, M Chakos, A Loebel, T Cooper, J Kane
Journal: American Journal of Psychiatry (1994)

The aim of this study was to determine the relation between plasma fluphenazine levels and clinical response in first-episode schizophrenic patients.Data from 36 first-episode schizophrenic or schizoaffective inpatients diagnosed according to the Research Diagnostic Criteria were evaluated. The patients received open, standardized treatment with fluphenazine, 20 mg/day, for at least 4 weeks. Psychopathology was assessed biweekly, and plasma fluphenazine levels were ascertained weekly. Patients were classified as responders or nonresponders, and correlations between their neuroleptic levels and ratings of psychopathologic and extrapyramidal symptoms were computed.Plasma fluphenazine levels for weeks 1 through 4 were significantly correlated with each other but were not correlated with age, gender, diagnosis, or race. Mean neuroleptic levels (weeks 3 and 4) were not different between responders and nonresponders and were not correlated with measures of psychopathology or extrapyramidal symptoms.These results do not indicate an association between plasma fluphenazine levels and response to treatment or extrapyramidal side effects in first-episode schizophrenia. The disparity between the results of this study and those of previous studies may be due to methodological differences or to a biologically based difference between first-episode and chronic patients.
Partial hospitalization: an update
Authors: S Parker, J L Knoll
Journal: American Journal of Psychiatry (1990)

As a treatment modality for serious mental disorders, partial hospitalization has been proven to have therapeutic and economic advantages. However, it has relatively low utilization and poor third-party reimbursement compared to the more traditional outpatient and inpatient treatments. The authors provide a review and update of the definitions, historical development, models, staffing, and referral patterns of partial hospitalization. They comment on the role of the psychiatrist as a member of the multidisciplinary team in this treatment setting.
“Bleak” future predicted for social care without urgent extra funding
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Social care in the UK faces a “bleak” future unless urgent investment is made to protect services and stop “worrying consequences for the NHS,” sector leaders have warned.

The Association of Directors of Adult Social Services (ADASS) said that letting local authorities raise council tax to invest solely in social care this year had failed to close the funding gap in the sector.

A survey of all 151 adult social services directors in England found that the government’s 2% precept, introduced in the 2015 autumn statement,1 was used by 93% of councils and raised a total of £380 million (€455m; $505m) this year.

But this amount did not even cover the £612m needed to pay for the implementation of the national …
Milk of Urate Bulla
Authors: Rachel C Robbins, Jess D Edison
Journal: New England Journal of Medicine (2016)

A 71-year-old man with a history of gout and renal transplantation presented with a new blister overlying the second interphalangeal joint just distal to a preexisting tophus on his hand. Examination of the fluid showed sheets of negatively birefringent crystals.
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Authors: Gary E Raskob, Nick van Es, Annelise Segers, Pantep Angchaisuksiri, Doyeun Oh, Zoltan Boda, Roger M Lyons, Karina Meijer, Ivan Gudz, Jeffrey I Weitz, George Zhang, Hans Lanz, Michele F Mercuri, Harry R Büller
Journal: The Lancet Haematology (2016)
Clinical and Immunological Characterisation of Coversin, a Novel Small Protein Inhibitor of Complement C5 with Potential As a Therapeutic Agent in PNH and Other Complement Mediated Disorders
Authors: Wynne H Weston-Davies, Miles A Nunn, Fernando O Pinto, Ian J Mackie, Stephen John Richards, Samuel J Machin, Raymond Prudo, Peter Hillmen
Journal: Blood (2014)
Ribosomal DNA Variation in Daphnia pulex
Authors: Teresa Crease, Michael Lynch
Journal: Molecular Biology and Evolution (1991)

Variation in the ribosomal DNA (rDNA) gene family was surveyed in five cyclically parthenogenetic populations of Daphnia pulex from central Illinois and in obligately parthenogenetic clones from Illinois and Ontario.A total of 37 distinct rDNA repeat types were identified on the basis of restriction-site and repeat-length polymorphism in a sample of 90 isolates.Repeat-type diversity was high within cyclic populations; however, individuals possessed only a small subset of the repeat-type variation present in each population.The distribution of repeat types within and among individuals suggested that new variants spread within rDNA arrays much faster than arrays carrying the variants spread within populations.This observation is contrary to a model developed by Ohta and Dover for strictly sexual organisms.Previous surveys of isozyme and mitochondrial DNA variation in these populations showed that gene flow among them is limited.Hierarchical analysis of rDNA restriction-site variation was consistent with this observation and showed that genetic divergence accumulates between populations for rDNA almost as rapidly as it does for single-copy nuclear genes (isozymes).Analysis of rDNA variation in obligately parthenogenetic clones provided evidence that both intra-and interchromosomal exchanges occur between rDNA arrays in the absence of meiosis.Moreover, individuals reproducing by obligate parthenogenesis possessed fewer rDNA repeat types, on average, than did individuals from cyclic populations, suggesting that there is a net loss of rDNA repeat-type variability within obligately clonal lineages over time.Preliminary analyses of two additional species, D. pulicaria and D. obtusa, revealed several restriction-site polymorphisms that were found in more than one of the three species.The existence of such shared polymorphisms advises caution in the use of multigene-family variation to infer phylogenies among species when levels of intraspecific variation have not been assessed.1.
Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).
Authors: Alan F. List, M.R. Baer, D. Steensma, A. Raza, J. Esposito, J. Virkus, J. Feigert, E. Besa, C. Paley
Journal: Blood (2007)
Cereblon (CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium
Authors: Elzbieta Iskierka-Jazdzewska, Anna Stepien, Federico Canzian, Alessandro Martino, Daniele Campa, Angelika Stein, Malgorzata Krawczyk-Kulis, Malwina Rybicka, Slawomira Kyrcz-Krzemien, Aleksandra K. Butrym, Grzegorz Mazur, Artur J. Jurczyszyn, Daria Zawirska, Norbert Grzasko, Waldemar Tomczak, Edyta Subocz, Marzena Watek, Marcin Pasiarski, Marcin Rymko, Malgorzata Calbecka, Agnieszka Druzd-Sitek, Jan Walewski, Marcin Kruszewski, Malgorzata Razny, Jan M Zaucha, Marek Dudzinski, Pawel Gaj, Krzysztof Warzocha, Krzysztof Jamroziak
Journal: Blood (2014)
Lesional CD4<sup>+</sup> IFN-γ<sup>+</sup> cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis
Authors: Takashi Maehara, Hamid Mattoo, Miho Ohta, Vinay S Mahajan, Masafumi Moriyama, Masaki Yamauchi, Jefte Drijvers, Seiji Nakamura, John H Stone, Shiv S Pillai
Journal: Annals of the Rheumatic Diseases (2016)

IgG4-related disease (IgG4-RD) is a chronic, systemic, inflammatory condition of unknown aetiology. We have recently described clonally expanded circulating CD4+ cytotoxic T lymphocytes (CTLs) in IgG4-RD that infiltrate affected tissues where they secrete interleukin (IL)-1β and transforming growth factor -β1 (TGF-β1). In this study, we sought to examine the role of CD4+ CTLs in the pathogenesis of IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS) and to determine whether these cells secrete interferon-gamma (IFN-γ) at lesional sites.Salivary glands of 25 patients with IgG4-DS, 22 patients with Sjögren's syndrome (SS), 12 patients with chronic sialoadenitis (CS) and 12 healthy controls were analysed in this study. Gene expression analysis was performed on submandibular glands (SMGs) from five patients with IgG4-DS, three with CS and three healthy controls. Infiltrating CD4+ CTLs were examined by quantitative multicolour imaging in tissue samples from 20 patients with IgG4-DS, 22 patients with SS, 9 patients with CS and 9 healthy controls.In IgG4-DS tissues, nine genes associated with CD4+ CTLs were overexpressed. The expression of granzyme A (GZMA) mRNA was significantly higher in samples from patients with IgG4-RD compared with corresponding tissues from SS and healthy controls. Quantitative imaging showed that infiltrating CD4+ GZMA+ CTLs were more abundant in patients with IgG4-DS than in the other groups. The ratio of CD4+GZMA+ CTLs in SMGs from patients with IgG4-DS correlated with serum IgG4 concentrations and the number of affected organs. A large fraction of CD4+GZMA+ CTLs in SMGs from patients with IgG4-DS secreted IFN-γ.The pathogenesis of IgG4-DS is associated with tissue infiltration by CD4+GZMA+ CTLs that secrete IFN-γ.